Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alogliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 0.86 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.86 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.86 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alogliptin SCHEMBL30216225 | 1.00 | DPP4 (0.86) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL476231 | 1.00 | DPP4 (0.86) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL16246767 | 1.00 | DPP4 (0.86) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL29352995 | 0.93 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL17036596 | 0.93 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL174188 | 0.93 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL121028 | 0.93 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL475872 | 0.92 | DPP4 (0.98) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL17781892 | 0.92 | DPP4 (0.98) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL476292 | 0.91 | DPP4 (0.85) | DPP4OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306764-A1 | CRYSTALLINE FORM OF AN ORGANIC COMPOUND | SANDOZ AG (CH) | 2011-12-15 | — | — | US | claimed |
| EP-2379522-A1 | CRYSTALLINE FORM OF AN ORGANIC COMPOUND | Sandoz AG (CH) | 2011-10-26 | — | — | EP | claimed |
| WO-2010072680-A1 | CRYSTALLINE FORM OF AN ORGANIC COMPOUND | SANDOZ AG (CH) | 2010-07-01 | — | — | WO | claimed |
| US-20210340133-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| CN-102079743-B | Dipeptidyl peptidase inhibitors | 武田药品工业株式会社 | 2020-08-25 | — | — | CN | disclosed |
| CN-102134231-B | Dipeptidyl peptidase inhibitors | 武田药品工业株式会社 | 2020-08-04 | — | — | CN | disclosed |
| CN-102134229-B | Dipeptidyl peptidase inhibitors | 武田药品工业株式会社 | 2020-08-04 | — | — | CN | disclosed |
| EP-3323818-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2018-05-23 | — | — | EP | disclosed |
| US-20180079741-A1 | PROCESS FOR PRODUCING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-2379522-B1 | CRYSTALLINE FORM OF ALOGLIPTIN | SANDOZ AG (CH) | 2018-02-28 | — | — | EP | disclosed |
| EP-1924567-A2 | PROCESS FOR THE PREPARATION OF PYRIMIDINEDIONE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-20080108807-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | FENG JUN | 2008-05-08 | — | — | US | disclosed |
| US-20080108808-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | FENG JUN | 2008-05-08 | — | — | US | disclosed |
| US-20080003283-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY, INC. (JP) | 2008-01-03 | — | — | US | disclosed |
| WO-2007035629-A2 | PROCESS FOR THE PREPARATION OF PYRIMIDINEDIONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007035372-A2 | POLYMORPHS OF BENZOATE SALT OF 2-[[6-[(3R)-3-AMINO-1-PIPERIDINYL]-3,4-DIHYDRO-3-METHYL-2,4-DIOXO-1(2H)-PYRIMIDINYL]METHYL]-BENZONITRILE AND METHODS OF USE THEREFOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | WO | disclosed |
| US-20070066635-A1 | POLYMORPHS OF BENZOATE SALT OF 2-[[6-[(3R)-3-AMINO-1-PIPERIDINYL]-3,4-DIHYDRO-3-METHYL-2,4-DIOXO-1(2H)-PYRIMIDINYL]METHYL]-BENZONITRILE AND METHODS OF USE THEREFOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-22 | — | — | US | disclosed |
| US-20050261271-A1 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. | 2005-11-24 | — | — | US | disclosed |
| EP-1586571-A1 | Dipeptidyl peptidase inhibitors | Takeda San Diego, Inc. (US) | 2005-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108807-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP3, DPP9 | DPP4 1/4885OPRM1 2340/4885OPRK1 3648/4885 |
| US-20080003283-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP7, DPP3 | DPP4 1/4885OPRM1 3481/4885OPRK1 2838/4885 |
| US-20070066635-A1 | POLYMORPHS OF BENZOATE SALT OF 2-[[6-[(3R)-3-AMINO-1-PIPERIDINYL]-3,4-DIHYDRO-3-METHYL-2,4-DIOXO-1(2H)-PYRIMIDINYL]METHYL]-BENZONITRILE AND METHODS OF USE THEREFOR | BPNT1, SLC6A11, CYP1B1 | DPP4 302/4885OPRM1 326/4885OPRK1 404/4885 |
| US-20110306764-A1 | CRYSTALLINE FORM OF AN ORGANIC COMPOUND | CYP3A4, CYP4B1, CYP4X1 | DPP4 37/4885OPRM1 206/4885OPRK1 746/4885 |
| US-20180079741-A1 | PROCESS FOR PRODUCING HETEROCYCLIC COMPOUND | DHPS, QDPR, DPYD | DPP4 129/4885OPRM1 848/4885OPRK1 943/4885 |
| US-20210340133-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, GLP1R, SLC5A2 | DPP4 4/4885OPRM1 1034/4885OPRK1 1557/4885 |
| US-20050261271-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP9 | DPP4 1/4885OPRM1 2340/4885OPRK1 3648/4885 |
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | GPR119, GLP1R, DPP9 | DPP4 5/4885OPRM1 1209/4885OPRK1 1757/4885 |
| US-20080108808-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP3, DPP9 | DPP4 1/4885OPRM1 2340/4885OPRK1 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.